anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, virology, molecular biology. SUBSTANCE: invention relates to chimeric living infectious attenuated virus that is used for the development of chimeric flaviviral vaccines. Invention comprises chimeric living infectious attenuated virus including yellow fever virus where its nucleotide sequence encoding protein prM-E is deleted, truncated or mutated that results to block of expression of the functional protein prM-E. Also, genome of yellow fever virus comprises the incorporated nucleotide sequence encoding protein prM-E of the second distinguishing flavivirus such as that protein prM-E of the second flavivirus is expressed and nucleic acid molecule encoding this virus. The advantage of invention involves the development of chimeric viruses that can be used as living attenuated vaccines. EFFECT: valuable properties of vaccines. 18 cl, 7 dwg, 6 tbl
The invention discloses a preparation method and application of a novel tooth whitening repairing agent. Especially, a BODIPY (boron fluoride-dipyrromethene) compound is prepared into an aqueous solution with a concentration of 0.1-100 micromol/L, and then ingredients are employed to make the solution into a uniform paste. Specifically, the BODIPY compound has a structure shown as the specification. Experiments prove that the water-soluble BODIPY photodynamic whitening repairing agent provided by the invention has a simple preparation method, is safe and free of toxic or side effect, a BODIPY photosensitizer can achieve a high singlet oxygen quantum yield. With good water solubility, the novel tooth whitening repairing agent has good biocompatibility. The tooth whitening repairing agent prepared according to the method provided by the invention is convenient to use, can be operated independently at home, and has strong controllability, and the illumination time can be chosen according to a user's own whitening requirements. The whitening repairing agent not only has no damage to teeth, but also can repair the tooth surface enamel and perform remineralization, thus making the teeth white, smooth, glossy and bright. Thus, the novel tooth whitening repairing agent has a broad market application prospect.
A faster, easier procedure is great, but you want assurance that reducing chair time doesn't mean compromising on performance. KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.This advancement is the latest in 3M's 30-year history of developing proven and trusted glass ionomers.
Sand is an irritant to people and animals. Sand remover powder mixture comprised of 1%-99% bentonite clay (sodium bentonite, calcium bentonite, montmorillonite) combined with 1%-99% starch powder (maranta arundinacea, arrowroot, tapioca starch, rice starch, corn starch) removes sand from effected areas of skin and hair. In some embodiments sand remover powder can contain fragrance, stabilizers, and moisture reducers. Sand remover powder can be used to remove residue from hair as a dry shampoo and does not require water. Sand remover powder can be used in place of talc (baby powder) applications. Some sand remover powder embodiments can be ingested. Sand remover powder is an alternative to talc based powder or other body powder.
In this study, 107 trauma patients were examined. Patients were divided into two groups according to ICU results: survivors (Group 1) and deceased patients (Group2). Patients were rated in terms of age, Neutrophil lymphocyte ratio (NLR) , mean platelet volüme (MPV), lactat value, intensive care unit stay, APACHE 2 soring systems. Mortality rate and the factors affecting this rate were examined.

83 of the patients were male (77.58%) and 24 were female (22.42%). The mean age was 46 years. The mean value of lactate level was 3.25. MPV mean value was 10.34. NLR mean value was 8.23 and Apache 2 score mean value was 22.8. The average length of stay in hospital was 11.33 days. When the intergroup mortality was evaluated in terms of the relationship between continuous variables, there was a statistically significant difference in apache 2 score. No statistically significant difference was found between age, lactate, MPV, NRL and length of hospital stay.

NRL, MPV, Lactate levels were not suitable for evaluation of trauma patients as a early prognostic factor in the first day ICU admission. The investigators think that the use of trauma scoring systems such as apache 2 related to mortality during first hospitalization in ICU is more appropriate.
Cell-free DNA (cfDNA) scavenging represents a promising anti-inflammatory modality for autoimmune disease (AID) treatment. However, it remains challenging for existing systems to achieve inflammation-targeted cfDNA scavenging and the management of cfDNA-unrelated inflammatory pathways. Herein, inflammation-responsive polyion complex vesicles (PICsomes) are developed, bridging inflammation-instructed cfDNA scavenging, and methotrexate (MTX) delivery for AID management. A positively charged, PEGylated polypeptide with guanidine side chains (PEG-PG) is developed, which self-assembles with a negatively charged, cis-aconitic anhydride-modified poly-L-lysine (PC) to form the PICsomes and encapsulate MTX disodium salt. The neutrally charged PICsomes feature prolonged blood circulation after systemic administration, allowing for passive accumulation to the inflamed tissues. In the slightly acidic inflammatory microenvironment, PC transforms from negatively charged to positively charged, thereby disintegrating the PICsomes and liberating the PEG-PG and MTX. Consequently, PEG-PG-mediated cfDNA scavenging and MTX-mediated immunosuppression cooperate to inhibit inflammation and ameliorate the inflammatory microenvironment, promoting tissue repair in AID mouse models including collagen-induced arthritis and 2,4,6-trinitrobenzenesulfonic acid-induced colitis.
A patient support apparatus and a portable service tool are adapted to communicate with each other in order to allow a user of the service tool to wirelessly update software executed by the patient support apparatus. In some embodiments, the patient support apparatus displays a coded message that encodes network credentials (e.g. SSID, password, etc.) and the software tool is adapted to capture an image of the coded message, decode the message, and then set up a wireless network having the decoded network credentials. The patient support apparatus then automatically joins the network and receives one or more wireless software updates. The service tool may alternatively or additionally connect to a healthcare facility network and upload software to a server thereon, which then downloads the software to the patient support apparatus over the healthcare facility computer network.
OBJECTIVE: Patients with focal drug resistant epilepsy are excellent candidates for epilepsy surgery. Status epilepticus (SE) and seizure clusters (SC), described in a subset of patients, have both been associated with extended epileptogenic cerebral networks within one or both hemispheres. In this retrospective study, we were interested to determine if a history of SE or SC is associated with a worse surgical outcome.
METHODS: Data of 244 patients operated between 2000 to 2018 were reviewed, with a follow-up of at least 2 years. Patients with a previous history of SE or SC were compared to operated patients without these conditions (control group, CG).
RESULTS: We identified 27 (11%) and 38 (15.5%) patients with history of SE or SC, respectively. No difference in post-operative outcome was found for SE and SC patients. Compared to the control group, patients with a history of SE were diagnosed and operated significantly at earlier age(p = 0.01), and after a shorter duration of the disease (p = 0.027), but with a similar age of onset.
SIGNIFICANCE: A history of SE or SC was not associated with a worse post-operative prognosis. Earlier referral of SE patients for surgery suggests a heightened awareness regarding serious complications of recurrent SE by the referring neurologist or neuropediatrician. While the danger of SE is evident, policies to underline the impact for SC or very frequent seizures might be an efficient approach to accelerate patient referral also for this patient group.
This is an international, multicenter, double-blind, randomized, placebo-controlled trial. Following a 4 week screening period, patients with mild cognitive impairment (MCI), who are clinically at risk for development of Alzheimer's disease, will be randomized to treatment with either placebo or galantamine for 24 months with either placebo or a flexible dose of galantamine. Efficacy will be evaluated by measures of memory and cognition (Alzheimer's Disease Assessment Scale of cognition for MCI \[ADAS-cog/MCI\] and the Clinical Dementia Rating Sum of the Boxes \[CDR-SB\]), global severity of dementia (Clinical Dementia Rating \[CDR\]), functionality (Alzheimer's Disease Cooperative Study - Activities of Daily Living adapted to MCI \[ADCS-ADL/MCI\]), and changes on serial magnetic resonance imaging (MRI). Safety will be assessed using adverse event reports, vital signs, laboratory parameters, physical examination and electrocardiograms. The primary study hypothesis is that galantamine will improve memory deficits associated with mild cognitive impairment and therefore improve or stabilize the patient's cognitive abilities. A second study hypothesis is that treatment with galantamine slows or delays conversion of mild cognitive impairment to the dementia often associated with probable Alzheimer's disease in these patients. The third study hypothesis is that the treatment will be well tolerated by the patients. Galantamine hydrobromide immediate-release tablets (4, 8, and 12 milligrams (mg)) taken by mouth 2 times daily: 4 weeks at 8mg/day, 4 weeks at 16mg/day, increased to 24mg/day for the remainder of the 24-month trial. Dose may be reduced at investigator's discretion after 12 weeks.
BACKGROUND: A significant research gap exists regarding the role of tissue exosomes in intrauterine adhesions (IUAs). This study aims to investigate the involvement of miR-195-5p and its regulatory network in IUAs through the analysis of tissue exosomes.
METHODS: Exosomes from rat uterine tissue with intrauterine adhesions were analyzed via transcriptomics to identify downstream target genes of miR-195-5p, cross-referencing with the human endometrial transcriptomics database GSE224093. Dual luciferase labeling confirmed miRNA-target gene interactions. The therapeutic efficacy of a miR-195-5p agonist was assessed in vivo through HE staining, Masson staining, and mating tests. The mechanisms underlying extracellular matrix (ECM) deposition and myofibroblast transdifferentiation in endometrial fibrosis were investigated both in vitro and in vivo using RT-PCR, Western Blot, immunofluorescence, and immunohistochemistry. Migration ability of endometrial stromal cells was evaluated using CCK8, scratch tests, and Transwell assays. Finally, the clinical potential of miR-195-5p was compared with autologous adipose-derived mesenchymal stem cells.
RESULTS: The expression of miR-195-5p in uterine tissue exosomes from intrauterine adhesions was found to be decreased. Treatment with a miR-195-5p agonist resulted in improved endometrial health, reduced fibrosis, increased glandular density, and enhanced birth rates in rats. Both in vivo and in vitro experiments confirmed that miR-195-5p decreased ECM deposition, reduced myofibroblast transdifferentiation, and inhibited the migration of endometrial stromal cells. This was achieved through the downregulation of YAP expression in the Hippo pathway and the upregulation of Smad7. Notably, the therapeutic efficacy of miR-195-5p agonists was comparable to that of stem cell therapy, offering promising avenues for clinical application.
CONCLUSIONS: Differential expression of miR-195-5p in tissue exosomes can reduce ECM deposition and myofibroblast transdifferentiation, improving endometrial fibrosis by regulating the YAP-Smad7 pathway in the Hippo signaling cascade.
PCT No. PCT/FI94/00232 Sec. 371 Date May 8, 1996 Sec. 102(e) Date May 8, 1996 PCT Filed Jun. 2, 1994 PCT Pub. No. WO94/28867 PCT Pub. Date Dec. 22, 1994A less dusty, more stable and more easily handlable protector against UV light than previously is obtained by supplying it in the form of solid particles having a mean diameter of at minimum 10  mu m and containing, dispersed in 90-20 parts by weight of wax, 10-80 parts by weight of a pigment which reduces the penetration UV light and is made up of metal oxide particles of a mean primary particle diameter smaller than 0.150  mu m.
This is a multicentre, randomized, open label, blinded-endpoint trial that aims to investigate the effects of Human Urinary Kallidinogenase treatment on neurological outcomes, early cerebral perfusion in patients with acute anterior circulation ischemic stroke. Patients in intervention group will be given 0.15 peptide nucleic acids (PNA) Human Urinary Kallidinogenase concentrated solution for intravenous injection once a day for 10 days continuously, and those in the control group will be given conventional therapy. Both groups of patients will be on standard stroke care. In this study, patients who were eligible to the inclusion criteria and ineligible to the exclusion criteria will be randomly assigned into two groups by a 1:1 ratio after the informed consent form (ICF) was received. The total sample size will be 540. All patients will be followed up for 90 days. The primary outcome is the proportion of modified Rankin Scale 0-2. Besides, the investigators aimed to use computed tomography perfusion (CTP) evaluate the differences of ischemic penumbra volume and regional cerebral blood flow (rCBF) before and after treatment between intervention group and control group.

Furthermore, this study adopts adaptive design, prospectively stating interim analyses with specified stopping rules, which allow for the possibility of the study to terminate early based on either determination of study success or of the futility to continue further enrollment.
This is a prospective, multi-site, randomized study to evaluate the clinical utility of cWGS in each proband. Throughout this study, each proband will receive SOC testing as determined by the site clinical team. Upon enrollment in the study, each proband will be randomly assigned to the 15 day cWGS group or the SOC group. SOC is defined as the management of the proband's care under the same or similar conditions as if the proband was not enrolled in this study. A blood sample from each enrolled proband will be collected and shipped to the Illumina Clinical Services Laboratory ("ICSL"), which is Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited. ICSL will conduct cWGS testing with the TruGenome Undiagnosed Disease Test ("TruGenome Test"). The TruGenome Test cWGS results will be provided to the Principal Investigator (PI) or designee who will evaluate each proband test outcome based on the aggregate medical information, informed by the cWGS or SOC results.
One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin. At the end of immunotherapy, DFMO will be given to all subjects BID for 730 days.
This study aimed to explore the mechanism of Xiaoyu Xiezhuo decoction (XXD) on ischemia-reperfusion-induced acute kidney injury (IRI-AKI) using network pharmacology methods and gut microbiota analysis. A total of 1778 AKI-related targets were obtained, including 140 targets possibly regulated by AKI in XXD, indicating that the core targets were mainly enriched in inflammatory-related pathways, such as the IL-17 signaling pathway and TNF signaling pathway. The unilateral IRI-AKI animal model was established and randomly divided into four groups: the sham group, the AKI group, the sham + XXD group, and the AKI + XXD group. Compared with the rats in the AKI group, XXD improved not only renal function, urinary enzymes, and biomarkers of renal damage such as Kim-1, cystatin C, and serum inflammatory factors such as IL-17, TNF-α, IL-6, and IL 1-β, but also intestinal metabolites including lipopolysaccharides, d-lactic acid, indoxyl sulfate, p-cresyl sulfate, and short-chain fatty acids. XXD ameliorated renal and colonic pathological injury as well as inflammation and chemokine gene abundance, such as IL-17, TNF-α, IL-6, IL-1β, ICAM-1, and MCP-1, in AKI rats via the TLR4/NF-κB/NLRP3 pathway, reducing the AKI score, renal pathological damage, and improving the intestinal mucosa's inflammatory infiltration. It also repaired markers of the mucosal barrier, including claudin-1, occludin, and ZO-1. Compared with the rats in the AKI group, the α diversity was significantly increased, and the Chao1 index was significantly enhanced after XXD treatment in both the sham group and the AKI group. The treatment group significantly reversed this change in microbiota.
BACKGROUND: While COVID-19 is predominantly a respiratory disease, cardiovascular complications occur and are associated with worse outcomes. Electrocardiogram (ECG) abnormalities are frequently observed in hospitalized COVID-19 patients, some of which are associated with increased mortality. It is unclear whether ECG abnormalities occurring before hospitalization are associated with increased mortality. This quantitative systematic literature review aims to determine which ECG changes occurring before hospitalization are associated with mortality and discuss whether these findings can aid the assessment of patients and decision-making in the pre-hospital environment.
METHODS: A systematic search of the following digital databases was conducted: CINAL, PUBMED, MEDLINE, and Coronavirus Research Database. Eight cohort studies (primary papers) including COVID-19 patients with ECGs taken in the Emergency Department before hospitalization were selected for quantitative synthesis and results were obtained for the prevalence of ECG changes among survivors compared with non-survivors. Odds and hazard ratios for ECG abnormalities associated with mortality were also collected and compared.
RESULTS: Identification of ECG abnormalities on pre-hospitalization ECG is associated with increased mortality in COVID-19 patients. These ECG abnormalities include non-sinus rhythm, QTc prolongation, left bundle branch block, axis deviation, atrial fibrillation, atrial flutter, right ventricular strain patterns, ST segment changes, T wave abnormalities, and evidence of left ventricular hypertrophy.
CONCLUSION: Electrocardiogram assessment in the pre-hospital environment may be beneficial when assessing COVID-19 patients and could help identify patients at increased risk of mortality.
Dry powder formulations for inhalation and their use in the treatment diseases and conditions. The formulation contains a uniform blend of a first spray-dried powder and a second spray-dried powder. The first spray-dried powder contains spray-dried particles of a therapeutically active ingredient dispersed in a pharmaceutically acceptable hydrophobic excipient. The second spray-dried powder contains spray-dried particles formed from a pharmaceutically acceptable hydrophobic excipient but are substantially free of any therapeutically active ingredient. The active ingredient in the first spray-dried powder is loaded sufficiently high to compensate for the second spray-dried powder being substantially free of any active ingredient. A process for preparing such formulations is also described.
Dose escalation to the DIL(s) will be performed in the traditional Phase I 3+3 design. Patients will be treated in four cohorts (three patients per dose level) starting with a dose of 9 Gy to the DIL(s). If no dose limiting toxicity (DLT), defined below, is observed after 90 days, then an additional three patients will be entered at the next dose level. Dose to the DIL(s) will be escalated at 1 Gy increments until DLT is observed or if maximum dose level (60 Gy in 5 fractions of 12 Gy) is reached with no observed DLT. If one of the three patients experience a DLT at a particular dose level an additional three patients will be enrolled at that level. If two or more patients experience a DLT a lower dose level will be explored to define the maximum tolerated dose (MTD). The three patients within any cohort can be enrolled simultaneously or sequentially without any waiting period among them.
NEW MATERIAL:The compound of formula I (R is H or alkyl; Y and Z are same halogen, oxy anion or carboxylate or together form oxy anion, oxythio anion or dicarboxylate; n is integer). EXAMPLE:cis-Dichloro(8-aminomethylpyrrolizidine)platinum(II). USE:Antitumor agent having low renal toxicity. Since the compound has high solubility in water, an injection, capsule, granule, suppository, etc., having high absorbability can be prepared easily therefrom. PREPARATION:The compound of formula I wherein Y and Z are halogen can be produced by reacting the pyrrolizidine compound of formula II (e.g. 8- aminomethylpyrrolizidine) with the platinum compound of formula M2PtX4 (M is alkali metal; X is halogen) (e.g. potassium chloroplatinite).
PEDIATRIC NECROTIZING SOFT-TISSUE INFECTIONS. Necrotizing soft-tissue infections (NSTI) include necrotizing forms of fasciitis, myositis, and cellulitis. In children, these are extremely rare conditions with an estimated annual incidence of less than 0.1/100,000 patients aged 0-18 years in France. Nevertheless, the evolution can be very serious (6% mortality, higher than the mortality observed in paediatric intensive care units [PICU]), whereas the initial local symptoms are poor and can be falsely reassuring. The monitoring of a skin infection must be close in order not to ignore the evolution towards a NSTI. In this case, prompt transfer to a PICU with all the necessary technical facilities and used to the management of these rare conditions must be done. Early initiation of antibiotic treatment and aggressive haemodynamic resuscitation according to the latest Surviving Sepsis Campaign guidelines should be a priority. The paediatric surgeon should be called upon as soon as clinical suspicion arises and participate in the frequent clinical reassessment to determine the optimal time to perform the surgical treatment.